Inherent Immunogenicity or Lack Thereof of Pluripotent Stem Cells: Implications for Cell Replacement Therapy
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Donor-specific induced pluripotent stem cells (iPSCs) offer opportunities for personalized cell replacement therapeutic approaches due to their unlimited self-renewal potential and ability to differentiate into different somatic cells. A significant progress has been made toward generating iPSC lines that are free of integrating viral vectors, development of xeno-free culture conditions, and differentiation of pluripotent stem cells (PSCs) into functional somatic cell lineages. Since donor-specific iPSC lines are genetically identical to the individual, they are expected to be immunologically matched and these iPSC lines and their cellular derivatives are not expected to be immunologically rejected. However, studies in mouse models, utilizing rejection of teratomas as a model, have claimed that syngenic iPSC lines, especially the iPSC lines derived with integrating viral vectors, could be inherently immunogenic. This manuscript reviews current understanding of inherent immunogenicity of PSC lines, especially that of the human iPSC lines and their cellular derivatives, and strategies to overcome it.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence of immune response has been observed in autologous transplantations of iPSCs in mice and raises concerns for therapeutic potential in humans28–30.”
From Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic (2021) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276 · cited 1×
“Production of arginase-I in tumor microenvironment in known to inhibit T cells by depleting l-arginine from the microenvironment (36) and the hESC-mediated immune suppression has also been shown to utilize this mechanism, as provision of l-arginine mitigates hESC-mediated T cell suppression (37).”
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071 · cited 1×
“Furthermore, promising treatment modalities in preclinical models do not always produce matching outcomes in humans (30, 31).”
BackgroundThemeli, M., Kloss, C. C., Ciriello, G., Fedorov, V. D., Perna, F., Gonen, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2678 · Cited by 473
Drukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0188 · Cited by 402 · cited 14×
“Furthermore, these iPSC lines do not express MHC class II molecules but do express low levels of MHC class I molecules (14), in agreement with findings in hESC lines (13, 33, 42).”
BackgroundResultInfluentialGuha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.01.006 · Cited by 368 · cited 11×
“used 1 × 106 in their renal space teratoma induction experiments (8).”
BackgroundMethodInfluentialRoifman, C. M., Zhang, J., Chitayat, D., & Sharfe, N. (2000) · Blood · doi:10.1182/blood.v96.8.2803 · Cited by 177 · cited 1×
“Thy1 is a marker for mouse but not human T cells (24), interleukin-7 receptor (IL-7R) deficiency results in loss of both T and B cells in mouse (25) but only of T cells in humans (26) and Zap-70 deficiency results in loss of both CD4+ and CD8+ T cells in mouse but only of CD8+ T cells in humans (27).”
Background
Research works printed but not linked: 65
- Thomson, 1998, Embryonic stem cell lines derived from human blastocysts, Science, 282, 1145, 10.1126/science.282.5391.1145 · DOI · Paper page
- Takahashi, 2006, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell, 126, 663, 10.1016/j.cell.2006.07.024 · DOI · Paper page
- Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 · DOI · Paper page
- Yu, 2007, Induced pluripotent stem cell lines derived from human somatic cells, Science, 318, 1917, 10.1126/science.1151526 · DOI · Paper page
- Zhao, 2011, Immunogenicity of induced pluripotent stem cells, Nature, 474, 212, 10.1038/nature10135 · DOI · Paper page
- Okita, 2011, Immunogenicity of induced pluripotent stem cells, Circ Res, 109, 720, 10.1161/RES.0b013e318232e187 · DOI · Paper page
- Araki, 2013, Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells, Nature, 494, 100, 10.1038/nature11807 · DOI · Paper page
- Todorova, 2016, Brief report: immune microenvironment determines the immunogenicity of induced pluripotent stem cell derivatives, Stem Cells, 34, 510, 10.1002/stem.2227 · DOI
- Zhao, 2015, Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells, Cell Stem Cell, 17, 353, 10.1016/j.stem.2015.07.021 · DOI · Paper page
- de Almeida, 2014, Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance, Nat Commun, 5, 3903, 10.1038/ncomms4903 · DOI · Paper page
- Koch, 2008, Immunosuppression by embryonic stem cells, Stem Cells, 26, 89, 10.1634/stemcells.2007-0151 · DOI · Paper page
- Li, 2004, Human embryonic stem cells possess immune-privileged properties, Stem Cells, 22, 448, 10.1634/stemcells.22-4-448 · DOI · Paper page
- Chhabra, 2017, Human dendritic cell-derived induced pluripotent stem cell lines are not immunogenic, J Immunol, 198, 1875, 10.4049/jimmunol.1601676 · DOI
- Magliocca, 2006, Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression, Stem Cells Dev, 15, 707, 10.1089/scd.2006.15.707 · DOI
- Dressel, 2010, Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells, FASEB J, 24, 2164, 10.1096/fj.09-134957 · DOI · Paper page
- Kim, 2010, Epigenetic memory in induced pluripotent stem cells, Nature, 467, 285, 10.1038/nature09342 · DOI · Paper page
- Vaskova, 2013, “Epigenetic memory” phenomenon in induced pluripotent stem cells, Acta Naturae, 5, 15, 10.32607/20758251-2013-5-4-15-21 · DOI · Paper page
- Schnerch, 2010, Distinguishing between mouse and human pluripotent stem cell regulation: the best laid plans of mice and men, Stem Cells, 28, 419, 10.1002/stem.298 · DOI · Paper page
- Ginis, 2004, Differences between human and mouse embryonic stem cells, Dev Biol, 269, 360, 10.1016/j.ydbio.2003.12.034 · DOI · Paper page
- Suh, 2004, Human embryonic stem cells express a unique set of microRNAs, Dev Biol, 270, 488, 10.1016/j.ydbio.2004.02.019 · DOI · Paper page
- Mestas, 2004, Of mice and not men: differences between mouse and human immunology, J Immunol, 172, 2731, 10.4049/jimmunol.172.5.2731 · DOI · Paper page
- Sitnicka, 2003, Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells, Blood, 102, 881, 10.1182/blood-2002-06-1694 · DOI · Paper page
- Tokugawa, 1997, A molecular basis for species differences in Thy-1 expression patterns, Mol Immunol, 34, 1263, 10.1016/S0161-5890(98)00010-8 · DOI
- Peschon, 1994, Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice, J Exp Med, 180, 1955, 10.1084/jem.180.5.1955 · DOI · Paper page
- Elder, 2001, Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70, J Immunol, 166, 656, 10.4049/jimmunol.166.1.656 · DOI · Paper page
- Tibbetts, 2003, The death effector domain protein family: regulators of cellular homeostasis, Nat Immunol, 4, 404, 10.1038/ni0503-404 · DOI · Paper page
- Chun, 2002, Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency, Nature, 419, 395, 10.1038/nature01063 · DOI · Paper page
- Lublin, 1993, Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis, Autoimmunity, 16, 267, 10.3109/08916939309014645 · DOI · Paper page
- Drukker, 2004, Immunogenicity of human embryonic stem cells: can we achieve tolerance?, Springer Semin Immunopathol, 26, 201, 10.1007/s00281-004-0163-5 · DOI
- Segall, 1996, Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera, Blood, 88, 721, 10.1182/blood.V88.2.721.bloodjournal882721 · DOI
- Mohib, 2010, Human embryonic stem cell-extracts inhibit the differentiation and function of monocyte-derived dendritic cells, Stem Cell Rev, 6, 611, 10.1007/s12015-010-9185-7 · DOI
- Yachimovich-Cohen, 2010, Human embryonic stem cells suppress T cell responses via arginase I-dependent mechanism, J Immunol, 184, 1300, 10.4049/jimmunol.0804261 · DOI
- Rong, 2014, An effective approach to prevent immune rejection of human ESC-derived allografts, Cell Stem Cell, 14, 121, 10.1016/j.stem.2013.11.014 · DOI · Paper page
- Schuurhuis, 2006, Ins and outs of dendritic cells, Int Arch Allergy Immunol, 140, 53, 10.1159/000092002 · DOI
- Merad, 2013, The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting, Annu Rev Immunol, 31, 563, 10.1146/annurev-immunol-020711-074950 · DOI · Paper page
- Steinman, 2012, Decisions about dendritic cells: past, present, and future, Annu Rev Immunol, 30, 1, 10.1146/annurev-immunol-100311-102839 · DOI · Paper page
- Drukker, 2002, Characterization of the expression of MHC proteins in human embryonic stem cells, Proc Natl Acad Sci U S A, 99, 9864, 10.1073/pnas.142298299 · DOI · Paper page
- Lu, 2014, Negligible immunogenicity of induced pluripotent stem cells derived from human skin fibroblasts, PLoS One, 9, e114949, 10.1371/journal.pone.0114949 · DOI
- Morizane, 2013, Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate, Stem Cell Reports, 1, 283, 10.1016/j.stemcr.2013.08.007 · DOI · Paper page
- Koch, 2006, Complement-dependent control of teratoma formation by embryonic stem cells, J Immunol, 177, 4803, 10.4049/jimmunol.177.7.4803 · doi:10.4049/jimmunol.177.7.4803
- Albert, 1998, Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs, Nature, 392, 86, 10.1038/32183 · DOI · Paper page
- Kreisel, 2002, Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition, Nat Med, 8, 233, 10.1038/nm0302-233 · DOI · Paper page
- Swijnenburg, 2008, Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts, Proc Natl Acad Sci U S A, 105, 12991, 10.1073/pnas.0805802105 · DOI · Paper page
- Pearl, 2011, Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells, Cell Stem Cell, 8, 309, 10.1016/j.stem.2011.01.012 · DOI · Paper page
- Gibbons, 2008, Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism, Immunol Rev, 223, 334, 10.1111/j.1600-065X.2008.00636.x · DOI
- Waldmann, 2006, Regulatory T cells in transplantation, Semin Immunol, 18, 111, 10.1016/j.smim.2006.01.010 · DOI
- Chhabra, 2008, CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model, J Immunol, 181, 1063, 10.4049/jimmunol.181.2.1063 · DOI
- Mukherji, 1995, Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells, Proc Natl Acad Sci U S A, 92, 8078, 10.1073/pnas.92.17.8078 · DOI · Paper page
- Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514 · DOI · Paper page
- Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003 · DOI · Paper page
- Gilboa, 2007, DC-based cancer vaccines, J Clin Invest, 117, 1195, 10.1172/JCI31205 · DOI · Paper page
- Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842 · DOI · Paper page
- Chhabra, 2011, TCR-engineered, customized, antitumor T cells for cancer immunotherapy: advantages and limitations, ScientificWorldJournal, 11, 121, 10.1100/tsw.2011.10 · DOI
- Rosenberg, 2004, Cancer immunotherapy: moving beyond current vaccines, Nat Med, 10, 909, 10.1038/nm1100 · DOI · Paper page
- Ray, 2009, Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma, Clin Dermatol, 27, 603, 10.1016/j.clindermatol.2008.09.019 · doi:10.1016/j.clindermatol.2008.09.019
- Chhabra, 2008, Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35, Clin Immunol, 126, 251, 10.1016/j.clim.2007.11.011 · DOI
- Zhan, 2004, Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro, Lancet, 364, 163, 10.1016/S0140-6736(04)16629-4 · DOI · Paper page
- Woll, 2009, Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity, Blood, 113, 6094, 10.1182/blood-2008-06-165225 · DOI · Paper page
- Slukvin, 2006, Directed differentiation of human embryonic stem cells into functional dendritic cells through the myeloid pathway, J Immunol, 176, 2924, 10.4049/jimmunol.176.5.2924 · DOI · Paper page
- Galic, 2006, T lineage differentiation from human embryonic stem cells, Proc Natl Acad Sci U S A, 103, 11742, 10.1073/pnas.0604244103 · DOI
- Tseng, 2009, Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells, Regen Med, 4, 513, 10.2217/rme.09.25 · DOI
- Silk, 2012, Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells, Gene Ther, 19, 1035, 10.1038/gt.2011.177 · doi:10.1038/gt.2011.177
- Nishimura, 2013, Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation, Cell Stem Cell, 12, 114, 10.1016/j.stem.2012.11.002 · DOI · Paper page
- Vizcardo, 2013, Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells, Cell Stem Cell, 12, 31, 10.1016/j.stem.2012.12.006 · DOI · Paper page
- Knorr, 2010, Pluripotent stem cell-derived natural killer cells for cancer therapy, Transl Res, 156, 147, 10.1016/j.trsl.2010.07.008 · DOI · Paper page
Cited by
Colter, J., Murari, K., Biernaskie, J., & Kallos, M. S. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00183-7 · Cited by 33
Metadata
- Authors
- Chhabra, A.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2017-08-18
- Volume
- 8
- ISSN
- 1664-3224
- Cited by
- 15
- References
- 6
- Funders
- Connecticut Innovations (10-SCA-23 and 12-SCB-05)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.